Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures

Douglas R. Galasko, Elaine Peskind, Christopher M. Clark, Joseph F. Quinn, John M. Ringman, Gregory A. Jicha, Carl Cotman, Barbara Cottrell, Thomas J. Montine, Ronald G. Thomas, Paul Aisen

Research output: Contribution to journalArticle

209 Scopus citations

Abstract

Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. Design: Double-blind, placebo-controlled clinical trial. Setting: Academic medical centers. Participants: Subjects with mild to moderate Alzheimer disease. Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. Main Outcome Measures: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). Results: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau181 levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. Conclusions: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. Trial Registration: clinicaltrials.gov Identifier: NCT00117403.

Original languageEnglish (US)
Pages (from-to)836-841
Number of pages6
JournalArchives of Neurology
Volume69
Issue number7
DOIs
StatePublished - Jul 2012

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures'. Together they form a unique fingerprint.

  • Cite this

    Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., & Aisen, P. (2012). Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology, 69(7), 836-841. https://doi.org/10.1001/archneurol.2012.85